Effect of dihydroergokryptine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic and acromegalic subjects: evidence of potent and long-lasting pituitary dopamine receptor stimulation.
The endocrine effects of a relatively potent dopaminergic agent, dihydroergokryptine, have been studied in normal subjects, and in hyperprolactinaemic and acromegalic patients. A single 6 mg oral dose of the drug caused a marked, long lasting fall in prolactin (PRL) plasma levels in healthy subjects, in hyperprolactinaemic patients and in normoprolactinaemic acromegalics. Growth hormone (GH) levels decreased in 1-DOPA - responder, acromegalic patients, but dihydroergokryptine did not affect GH levels in normal volunteers or in 1-DOPA non-responder, acromegalic patients. The PRL- and GH- lowering activity of 6 mg dihydroergokryptine was significantly greater than that of 6 mg dihydroergocristine, and was similar to that of an oral dose of 500 mg 1-DOPA.
D000172:Acromegaly / Q000097:blood*; D000236:Adenoma / Q000378:metabolism; D000328:Adult; D000368:Aged; D004088:Dihydroergotoxine / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010902:Pituitary Gland / Q000187:drug effects*; D010911:Pituitary Neoplasms / Q000378:metabolism; D011388:Prolactin / Q000097:blood* / Q000378:metabolism; D011954:Receptors, Dopamine / Q000187:drug effects*; D013997:Time Factors
D011954:Receptors, Dopamine; D004088:Dihydroergotoxine; D007980:Levodopa; D011388:Prolactin; D013006:Growth Hormone